Toxoplasma infection, when acquired in pregnancy, can cause fetal infection with potentially serious consequences for the newborn infant. It is generally held that only infants of mothers who acquire a primary infection in pregnancy are at risk and on this basis prenatal serological screening programmes have been set up in some countries, notably France.' Over recent years there has been increasing pressure in the UK to follow a similar course.2 However, before any screening programme is introduced nationally, the benefits and risks of the programme, both clinical and financial, need to be fully assessed. As the pattern of infection and the distribution of disease may differ from country to country it is important when reviewing the information available to take this into account. What is the appropriate policy for one country may not always be appropriate for another.
A working party was recently set up by the Royal College of Obstetricians and Gynaecologists to review the available epidemiological and clinical information relating to toxoplasmosis in pregnancy and congenital toxoplasmosis and to advise on whether a prenatal screening programme should be introduced in the UK. On the basis of current evidence the group concluded that it was not appropriate at the present time to introduce a nationwide antenatal screening programme for toxoplasmosis in the UK but emphasised the need for further research in this area.3
The information required to assess the benefits and risks, clinical, psychological and financial, of introducing such a programme and to determine whether the classic criteria proposed by Wilson and Jungner4 are satisfied includes: an understanding of the natural history of the condition, the prevalence of immunity to toxoplasmosis in women of childbearing age in the UK, the incidence of acute infection in pregnancy, the risk of transmission of infection to the fetus, and the frequency and nature of damage, both short and long term. In addition, the sensitivity and specificity, and safety, of the screening and diagnostic tests, and the efficacy of the intervention must be established. Africa.5 There is a paucity of information on the incidence of infection in pregnancy in the UK but review of published studies carried out in a number of different locations in the UK suggests that this is in the order of two per 1000 pregnancies.6 But studies in Sweden7 and South Yorkshire8 based on stored blood samples show that seroprevalence has fallen markedly over the last 20 years. This points to a downward trend in the incidence of toxoplasmosis in the population generally suggesting a need for more current information on the seroprevalence of toxoplasmosis in women from different geographical areas. After maternal infection the overall risk of transmission to the fetus is about 40%. This ranges from only about 15% after exposure to infection in the first trimester to about 60% after exposure in the later stage of pregnancy.9 On the other hand, if the fetus is infected, the earlier in pregnancy the maternal infection the greater the risk of severe disease in the fetus. This information is based on prospective studies carried out Screening for toxoplasma infection in pregnancy The aim of the screening test is to identify maternal infection by detecting seroconversions among women who are seronegative for toxoplasma IgG antibody and by identifying those women who have toxoplasma IgM in the initial serum taken on booking. Numerous methods are available but there is a wide variation in the reported performance of these assays. The accepted reference test is the Sabin Feldman dye test, which measure both IgG and IgM antibodies but as this requires live, viable parasites it is difficult to perform outside a reference laboratory.
Tests based on the detection of IgM in sera may be difficult to interpret because of the difficulty in distinguishing recent gestational infection from prepregnancy toxoplasmosis because of the persistence of IgM. There are large individual variations in IgM response to toxoplasma infection and the use of a sensitive test may detect very low concentrations of IgM persisting from infection months or even years before conception. '3 Testing for seroconversion requires repeated samples in all women seronegative at booking. In the UK this would necessitate the retesting of 80% of women at intervals during pregnancy in contrast to France where only 20% of pregnant women are susceptible and require repeat testing. Because of the cost implications it has been suggested that in the UK only one or two repeat samples might be sufficient. This would have disadvantages as delay in treatment after the onset of maternal infection is likely to decrease its efficacy.
The sensitivity and specificity of the screening test in predicting fetal infection is critical to the performance of a screening programme. Even highly specific tests generate large numbers of false positive results when the condition being screened for is uncommon. If one assumes an incidence of two per 1000 and a screening test with a 99% sensitivity and a 99% specificity, of every 100 women testing positive 17 
